Edwards Lifesciences Corporation, the world leader in the science of heart valves, opened on Thursday its new manufacturing facility in Singapore to meet the demand for technologically advanced tissue heart value replacement products, dpa reported.
The facility also serves as the headquarters for Asia-Pacific operations, one of the company's fastest growing regions, said Donald Bobo, Jr, corporate vice president.
"We look forward to serving more patients around the world through our heart valve operations in the United States, Switzerland, and now, Singapore," Bobo said.
Headquartered in Irvine, California, Edwards treats advanced cardiovascular disease with its heart valve therapies, critical care and vascular technologies.
Cardiovascular disease is the leading cause of death in the world and expected to increase, Bobo said.
He attributed the anticipated hike to "increasing aging populations" and the "progressive nature of the disease, which worsens over time."
Edwards, which is celebrating 50 years of partnering with clinicians to develop life-saving innovations, sells brands in 100 countries.
"Another factor increasing growth is the continued economic development in nations around the world, which allow more resources to be invested in treating chronic" cases, he said.